Role of PI3K/AKT/mTOR in Cancer Signaling

Owusu-Brackett, Nicci; Shariati, Maryam; Meric‐Bernstam, Funda

doi:10.1007/978-3-319-95228-4_20

Cited by 22 publications

(17 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is an additional negative regulator of PIP 3 , known as INPP4B (inositol polyphosphate-4-phosphatase type II B), which acts on the 4' phosphate, although this is less well understood and has not been studied in any detail in lymphocytes. Highlighting the importance of proper PI3K regulation, loss-of-function mutations in PTEN or SHIP have been linked to tumorigenesis 19,20 . Expression of PTEN appears to be particularly important, as homozygous loss of PTEN leads to early lethality, by embryonic day 7.5 in mice 21 .…”

Section: Negative Regulators Of Pi3k Signaling In Lymphocytesmentioning

confidence: 99%

Control of T lymphocyte fate decisions by PI3K signaling

Murter

Kane

2020

F1000Res

View full text Add to dashboard Cite

Virtually all aspects of T and B lymphocyte development, homeostasis, activation, and effector function are impacted by the interaction of their clonally distributed antigen receptors with antigens encountered in their respective environments. Antigen receptors mediate their effects by modulating intracellular signaling pathways that ultimately impinge on the cytoskeleton, bioenergetic pathways, transcription, and translation. Although these signaling pathways are rather well described at this point, especially those steps that are most receptor-proximal, how such pathways contribute to more quantitative aspects of lymphocyte function is still being elucidated. One of the signaling pathways that appears to be involved in this “tuning” process is controlled by the lipid kinase PI3K. Here we review recent key findings regarding both the triggering/enhancement of PI3K signals (via BCAP and ICOS) as well as their regulation (via PIK3IP1 and PHLPP) and how these signals integrate and determine cellular processes. Lymphocytes display tremendous functional plasticity, adjusting their metabolism and gene expression programs to specific conditions depending on their tissue of residence and the nature of the infectious threat to which they are responding. We give an overview of recent findings that have contributed to this model, with a focus on T cells, including what has been learned from patients with gain-of-function mutations in PI3K as well as lessons from cancer immunotherapy approaches.

show abstract

Section: Negative Regulators Of Pi3k Signaling In Lymphocytesmentioning

confidence: 99%

Control of T lymphocyte fate decisions by PI3K signaling

Murter

Kane

2020

F1000Res

View full text Add to dashboard Cite

show abstract

“…Class Iβ kinases consist of two catalytic and regulatory subunits, including p110γ and p101, respectively. PI3K activation occurs following binding to the tyrosine kinase receptor (RTK) directly or through the IRS protein 14 . However, this enzyme can be activated by G protein‐coupled receptor (GPCR) and RAS protein activation 15 .…”

Section: Pi3 Kinas Signaling and Cancermentioning

confidence: 99%

PI3 kinase signaling pathway in hematopoietic cancers: A glance in miRNA's role

Roshandel

Noorazar

Farhadihosseinabadi

et al. 2021

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Hematopoietic cancers are among the most common malignancies worldwide, which are divided into different types depending on the origin of tumor cells. In recent years, the pivotal role of different signaling pathways in the onset and progression of these cancer types has been well established. One of these pathways, whose role in blood malignancies has been well-defined, is PI3K/mTOR/AKT axis. The signaling pathway involves in a wide variety of important biological events in cells. It is clear that dysregulation of mediators involved in PI3 kinase signaling takes a pivotal role in cancer development. Considering the undeniable role of miRNAs, as one of the well-known families of non-coding RNAs, in gene regulation, we aimed to review the role of miR-NAs in regulation of PI3 kinase signaling effectors in hematopoietic cancers.

show abstract

“…The mTOR complexes are activated by AKT and regulate several cell growth functions including protein synthesis, cell survival and inhibition of autophagy [14]. Recent data indicate that PI3K signaling is frequently activated in several human malignancies including breast cancer and prolonged activation of PI3K signaling is related to a poor prognosis and resistance to chemotherapy [15,16].…”

Section: Pi3k/akt/mtor Signaling Pathwaymentioning

confidence: 99%

Role of regulatory miRNAs of the PI3K/AKT signaling pathway in the pathogenesis of breast cancer

Rahmani

Ferns

Talebian

et al. 2020

Gene

View full text Add to dashboard Cite

Breast cancer is one of the most common tumors in women. Current data indicate that the overexpression of some microRNAs (miRNAs) is associated with breast cancer, in relation to stage, tumor size and potential for metastasis. Some studies have reported that miRNAs have critical roles in cellular processes implicated in breast cancer cell growth, migration and metastasis by targeting the PI3K/AKT oncogenic signaling pathway. Therefore, identifying novel regulatory miRNAs for this oncogenic pathway and discovery of their related target genes may represent a promising therapeutic approach for breast cancer therapy. This review highlights the recent findings about the potential role of PI3K/AKT signaling regulatory miRNAs in breast cancer tumorigenesis.

show abstract

Role of PI3K/AKT/mTOR in Cancer Signaling

Cited by 22 publications

References 11 publications

Control of T lymphocyte fate decisions by PI3K signaling

Control of T lymphocyte fate decisions by PI3K signaling

PI3 kinase signaling pathway in hematopoietic cancers: A glance in miRNA's role

Role of regulatory miRNAs of the PI3K/AKT signaling pathway in the pathogenesis of breast cancer

Contact Info

Product

Resources

About